Survivin expression in human osteosarcoma is a marker for survival

被引:121
作者
Trieb, K
Lehner, R
Stulnig, T
Sulzbacher, I
Shroyer, KR
机构
[1] Univ Vienna, Dept Internal Med 3, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Orthopaed, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Pathol, A-1090 Vienna, Austria
[4] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2003年 / 29卷 / 04期
关键词
survivin; osteosarcoma; expression; survival;
D O I
10.1053/ejso.2002.1415
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Osteosarcoma is the most frequent malignant bone tumor with a peak incidence in the second and third decade of life. Evaluation of prognosis of patients with osteosarcoma is limited to clinical parameters whereas molecular markers of tumor aggression have not yet been identified. Inhibition of apoptotic cell death could play a role in the development or progression of neoplasia. Survivin is a member of the inhibitor of apoptosis (IAP) protein gene family and is expressed both during normal fetal development and in human cancer. Methods: The localization and distribution of survivin was investigated immunohistochemically in high-grade osteosarcomas by an indirect immunoperoxidase method. Results: Survivin was detected in the cytoplasm in 23/40 and in the nucleus in 20/40 cases of osteosarcoma. Nuclear localization of survivin expression was significantly correlated with a prolonged survival (P = 0.0347) but cytoplasmic staining showed no correlation with patient outcome. Conclusions: The results of this study indicates that the evaluation of survivin expression might be a useful prognostic marker in osteosarcoma. Patients with osteosarcoma exhibiting nuclear survivin expression could potentially benefit from stratification of neoadjuvant chemotherapy. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:379 / 382
页数:4
相关论文
共 12 条
[11]  
Lu CD, 1998, CANCER RES, V58, P1808
[12]   Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients [J].
Okada, E ;
Murai, Y ;
Matsui, K ;
Isizawa, S ;
Cheng, CM ;
Masuda, M ;
Takano, Y .
CANCER LETTERS, 2001, 163 (01) :109-116